NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis $2.32 -0.12 (-4.92%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$2.35 +0.03 (+1.29%) As of 10/23/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CytomX Therapeutics Stock (NASDAQ:CTMX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CytomX Therapeutics alerts:Sign Up Key Stats Today's Range$2.31▼$2.4250-Day Range$2.23▼$3.7252-Week Range$2.20▼$8.21Volume4.37 million shsAverage Volume3.14 million shsMarket Capitalization$505.53 millionP/E RatioN/ADividend YieldN/APrice Target$11.90Consensus RatingModerate Buy Company Overview CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites. CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines. Its pipeline has included oncology candidates directed at targets such as EGFR, CD3, and CEACAM5, with programs being evaluated in areas including solid tumors and hematologic malignancies. These medicines remain investigational and have not been established as approved commercial products. Founded in 2008 and headquartered in South San Francisco, California, CytomX has conducted research and clinical development activities for patients in the United States and other international markets. The company has also pursued collaborations with larger pharmaceutical companies, including agreements involving the development of Probody-based therapeutics. CytomX’s shares trade on the Nasdaq under the symbol CTMX.AI Generated. May Contain Errors. Read More CytomX Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreCTMX MarketRank™: 2.742477162815 of 5 starsCytomX Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 440th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCytomX Therapeutics has a consensus price target of $11.90, representing about 412.9% upside from its current price of $2.32.Amount of Analyst CoverageCytomX Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CytomX Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytomX Therapeutics has a P/B Ratio of 4.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CytomX Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.47% of the float of CytomX Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 8.67.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 5.63%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.61 News SentimentCytomX Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CytomX Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for CTMX on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat Follows3 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.80% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTMX Stock News HeadlinesCytomX Therapeutics Sees Unusually Large Options Volume (NASDAQ:CTMX)October 23 at 2:13 AM | americanbankingnews.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Has Consensus Target Price of $11.90 According to AnalystsOctober 22 at 2:15 AM | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 25 at 1:00 AM | Behind the Markets (Ad)CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comCytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - SlideshowSeptember 10, 2026 | seekingalpha.comCytomX Therapeutics to Present at Upcoming September Investor ConferencesSeptember 1, 2026 | globenewswire.comCytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)August 27, 2026 | globenewswire.comCytomX Therapeutics: Promising Varseta-M With Comfortable RunwayAugust 12, 2026 | seekingalpha.comSee More Headlines CTMX Stock Analysis - Frequently Asked Questions How have CTMX shares performed this year? CytomX Therapeutics' stock was trading at $4.26 at the start of the year. Since then, CTMX shares have decreased by 45.5% and is now trading at $2.32. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.01. The biotechnology company earned $1.42 million during the quarter, compared to analysts' expectations of $12.39 million. CytomX Therapeutics had a negative net margin of 435.21% and a negative trailing twelve-month return on equity of 38.46%. Read the conference call transcript. When did CytomX Therapeutics IPO? CytomX Therapeutics (CTMX) raised $100 million in an IPO on Thursday, October 8th 2015. The company issued 6,666,667 shares at $14.00-$16.00 per share. Who are CytomX Therapeutics' major shareholders? CytomX Therapeutics' top institutional investors include Assenagon Asset Management S.A. (0.54%) and Robertson Stephens Wealth Management LLC (0.10%). Insiders that own company stock include Sean A Mccarthy, Marcia Belvin, Christopher Ogden, Yu-Waye Chu, Lloyd A Rowland and Jeffrey B Landau. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), SoundHound AI (SOUN), Palantir Technologies (PLTR), Advanced Micro Devices (AMD) and Tesla (TSLA). Company Calendar Last Earnings8/06/2026Today10/24/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, CTMX's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CTMX CIK1501989 Webwww.cytomx.com Phone(650) 515-3185Fax650-351-0353Employees69Year Founded2008Price Target and Rating Average Price Target for CytomX Therapeutics$11.90 High Price Target$16.00 Low Price Target$6.00 Potential Upside/Downside+412.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.37 million Net Margins-435.21% Pretax Margin-433.95% Return on Equity-38.46% Return on Assets-30.33% Debt Debt-to-Equity RatioN/A Current Ratio9.36 Quick Ratio9.36 Sales & Book Value Annual Sales$76.20 million Price / Sales6.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book4.00Miscellaneous Outstanding Shares217,900,000Free Float209,619,000Market Cap$505.53 million OptionableOptionable Beta2.21 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:CTMX) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
